Ciclopirox Topical Solution 8pct Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Ciclopirox: Topical solution (8%)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Ciclopirox Nail Lacquer 8% Sol
Drug Image file default-drug-image.png
Ciclopirox Nail Lacquer 8% Sol
Drug Image file default-drug-image.png
Ciclopirox Nail Lacquer 8% Sol
Drug Image file default-drug-image.png
Ciclopirox Nail Lacquer 8% Sol
Drug Image file default-drug-image.png
Ciclopirox Nail Lacquer 8% Sol

What is this Medicine?

CICLOPIROX (sye kloe PEER ox) NAIL SOLUTION is an antifungal medicine. It used to treat fungal infections of the nails.

Similar Brand Name Drugs : Penlac: Topical solution (8%)
CVS Pharmacy Patient Statistics for Ciclopirox: Topical solution(8%)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information
Select a Medication

Ciclopirox Olamine Nail Lacquer 8% Topical Solution

NDC: 458020141
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Onychomycosis

Storage Information
Avoid exposure to heat
Store at room temperature (between 59 to 86 degrees F)
Protect from light
Ciclopirox Olamine Nail Lacquer 8% Topical Solution

Reported Side Effects for Ciclopirox Olamine Nail Lacquer 8% Topical Solution

Hair Loss Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Allergic Skin Reaction Incidence:
<5.0%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
<5.0%*
Severity: MILD
Onset: RAPID
Dry Skin Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Drug-Induced Acne Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Skin Redness Incidence:
1.0-46.0%*
Severity: MODERATE
Onset: EARLY
Nail Discoloration Incidence:
1.0-2.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Ciclopirox

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.